Aclaris stockholders approve doubling of authorized shares to 200M at annual meeting

Aclaris Therapeutics, Inc.

Amendment to authorized common stock from 100M to 200M shares approved: 60.7M for, 547K against, 3.4M abstain.
All three director nominees elected: Mehra 58.4M for, Powell 39.3M for, Gowen 57.3M for (Powell had 20.6M withheld).
Advisory say-on-pay approved: 58.6M for, 1.2M against, 28K abstain.
Ratification of PwC as auditor approved: 64.7M for, 16K against, 13K abstain.
Meeting turnout: 91.56% of 70.7M outstanding shares represented.

Key facts

Extracted from this filing and checked against the source text.

Shareholder Votes SEC 8-K Item 5.07 confidence 1.0

Aclaris Therapeutics, Inc. shareholders approved Approval of an amendment to the Company’s Amended and Restated Certificate of Incorporation to increase the authorized number of shares of common stock from 100,000,000 shares to 200,000,000 shares at the 2023-06-01 meeting.

Proposal: charter amendment
Outcome: passed
Meeting: 2023-06-01

Exact text from the filing

Proposal No. 3 : Approval of an amendment to the Company’s Amended and Restated Certificate of Incorporation to increase the authorized number of shares of common stock from 100,000,000 shares to 200,000,000 shares .

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 1.0

Aclaris Therapeutics, Inc. shareholders approved Advisory approval of the compensation of the Company’s named executive officers at the 2023-06-01 meeting.

Proposal: say on pay
Outcome: passed
Meeting: 2023-06-01

Exact text from the filing

Proposal No. 2 : Advisory approval of the compensation of the Company’s named executive officers, as disclosed in the Proxy Statement.

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 1.0

Aclaris Therapeutics, Inc. shareholders approved Election of three nominees to serve as directors at the 2023-06-01 meeting.

Proposal: director election
Outcome: passed
Meeting: 2023-06-01

Exact text from the filing

Proposal No. 1 : Election of three nominees to serve as directors on the Board of Directors until the 2026 annual meeting of stockholders and until their respective successors are elected and qualified.

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 1.0

Aclaris Therapeutics, Inc. shareholders approved Ratification of the appointment of PricewaterhouseCoopers LLP as independent registered public accounting firm for the fiscal year ending December 31, 2023 at the 2023-06-01 meeting.

Proposal: auditor ratification
Outcome: passed
Meeting: 2023-06-01

Exact text from the filing

Proposal No. 4 : Ratification of the appointment of PricewaterhouseCoopers LLP as independent registered public accounting firm for the fiscal year ending December 31, 2023.

View on SEC.gov

Browse all shareholder votes →

Aclaris Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001558370-23-010763

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.